EA202091420A1 - Радиоактивное мечение полипептидов - Google Patents

Радиоактивное мечение полипептидов

Info

Publication number
EA202091420A1
EA202091420A1 EA202091420A EA202091420A EA202091420A1 EA 202091420 A1 EA202091420 A1 EA 202091420A1 EA 202091420 A EA202091420 A EA 202091420A EA 202091420 A EA202091420 A EA 202091420A EA 202091420 A1 EA202091420 A1 EA 202091420A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
radioactive tagging
radioactive
tagging
methods
Prior art date
Application number
EA202091420A
Other languages
English (en)
Inventor
Вадим Дудкин
Шалом Голдберг
Джозеф Эрхардт
Рис Салтер
Тереза М. Макдевитт
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Publication of EA202091420A1 publication Critical patent/EA202091420A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Описаны улучшенные способы радиоактивного мечения антител с применением клик-химии. Также описаны фармацевтические композиции и применения, связанные с радиоактивно меченными антителами, полученными данными способами.
EA202091420A 2017-12-18 2018-12-17 Радиоактивное мечение полипептидов EA202091420A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762599830P 2017-12-18 2017-12-18
PCT/US2018/065913 WO2019125982A1 (en) 2017-12-18 2018-12-17 Radiolabeling of polypeptides

Publications (1)

Publication Number Publication Date
EA202091420A1 true EA202091420A1 (ru) 2020-09-10

Family

ID=65003549

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091420A EA202091420A1 (ru) 2017-12-18 2018-12-17 Радиоактивное мечение полипептидов

Country Status (15)

Country Link
US (1) US20210017099A1 (ru)
EP (1) EP3727474A1 (ru)
JP (2) JP2021506842A (ru)
KR (1) KR20200100094A (ru)
CN (1) CN111491670A (ru)
AU (1) AU2018388467A1 (ru)
BR (1) BR112020012099A2 (ru)
CA (1) CA3085465A1 (ru)
EA (1) EA202091420A1 (ru)
IL (1) IL275242A (ru)
MX (1) MX2020006395A (ru)
PH (1) PH12020550690A1 (ru)
SG (1) SG11202004906QA (ru)
WO (1) WO2019125982A1 (ru)
ZA (1) ZA202004424B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200303A1 (ar) * 2018-05-24 2020-11-23 Janssen Biotech Inc عوامل ربط psma واستخداماتها
KR20220002899A (ko) * 2019-04-19 2022-01-07 얀센 바이오테크 인코포레이티드 항-psma/cd3 항체로 전립선암을 치료하는 방법
BR112021022237A2 (pt) 2019-05-10 2022-03-29 Janssen Biotech Inc Queladores macrocíclicos e métodos de uso dos mesmos
JP7315004B2 (ja) * 2019-07-30 2023-07-26 Ｊｆｅエンジニアリング株式会社 ジルコニウム錯体の合成方法
CN114555132A (zh) 2019-10-18 2022-05-27 日本医事物理股份有限公司 放射性金属标记抗体的制造方法
CN114929717A (zh) * 2020-01-16 2022-08-19 杰富意工程技术株式会社 锆络合物的合成方法
BR112022018176A2 (pt) 2020-03-13 2022-12-06 Janssen Biotech Inc Materiais e métodos para ligação de siglec-3/cd33
JP2023527149A (ja) * 2020-05-19 2023-06-27 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ポリペプチドの処理および分析のための方法、システムおよびキット
AU2021361746A1 (en) * 2020-10-16 2023-06-22 Nihon Medi-Physics Co., Ltd. Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
EP4317152A1 (en) 2021-03-26 2024-02-07 Nihon Medi-Physics Co., Ltd. Compound, method for producing and method for storing compound, method for producing targeting agent, and composition
KR20230163487A (ko) * 2021-03-31 2023-11-30 니혼 메디피직스 가부시키가이샤 항egfr 항체의 방사성 복합체 및 방사성 의약
EP4337254A1 (en) * 2021-05-11 2024-03-20 Northeastern University Site-specific modification of glycoproteins through transglutaminase-mediated conjugation
WO2023190402A1 (ja) * 2022-03-30 2023-10-05 日本メジフィジックス株式会社 複合体の製造方法
WO2024030772A1 (en) * 2022-08-01 2024-02-08 Portland State University High relaxivity contrast agents and stereoselective preparation
WO2024059908A1 (en) * 2022-09-21 2024-03-28 The University Of Melbourne Radiolabelled compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US20080220448A1 (en) * 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
ES2627909T3 (es) * 2009-07-15 2017-08-01 Diatech Holdings, Inc. Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos
US10434197B2 (en) 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
AU2011336396B2 (en) * 2010-12-02 2016-02-04 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
EP2726494B1 (en) * 2011-06-28 2017-01-04 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN104704359A (zh) * 2012-10-25 2015-06-10 生命科技公司 糖蛋白酶介导位点特异性放射性标记的方法和组合物
WO2015057066A1 (en) * 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
CA2949365A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
US10758895B2 (en) * 2014-09-30 2020-09-01 University of Pittsburgh—of the Commonwealth System of Higher Education Cu(I)-catalyzed azide-alkyne cycloadditions (CuAAC) ligands and methods for carrying out Cu(I)-catalyzed azide-alkyne cycloaddition reactions
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes

Also Published As

Publication number Publication date
SG11202004906QA (en) 2020-07-29
CN111491670A (zh) 2020-08-04
WO2019125982A1 (en) 2019-06-27
PH12020550690A1 (en) 2021-04-12
JP2021506842A (ja) 2021-02-22
ZA202004424B (en) 2022-06-29
US20210017099A1 (en) 2021-01-21
IL275242A (en) 2020-07-30
JP2023078366A (ja) 2023-06-06
EP3727474A1 (en) 2020-10-28
AU2018388467A1 (en) 2020-06-11
BR112020012099A2 (pt) 2020-11-17
MX2020006395A (es) 2020-12-03
CA3085465A1 (en) 2019-06-27
KR20200100094A (ko) 2020-08-25

Similar Documents

Publication Publication Date Title
EA202091420A1 (ru) Радиоактивное мечение полипептидов
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
BR112019012343A2 (pt) anticorpos il-11ra
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
EA201990017A1 (ru) Антитела к миостатину и способы их применения
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
BR112019012342A2 (pt) anticorpos il-11
BR112018006237A2 (pt) proteínas de ligação a pd-1 e métodos de uso das mesmas
MY198059A (en) Anti-ox40 antibodies and their uses
BR112018003186A2 (pt) anticorpos anti-pd-1 e seus métodos de uso
AR101844A1 (es) Anticuerpos y conjugados modificados genéticamente con cisteína
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado